MannKind Corporation is a biopharmaceutical company that develops and commercializes treatments for cardiometabolic and orphan lung diseases through its proprietary Technosphere dry-powder inhalation platform. The company generates revenue through direct U.S. commercialization of three cardiometabolic products—Afrezza (inhaled insulin), Furoscix (subcutaneous furosemide), and V-Go (patch-based insulin delivery)—as well as royalties and milestone payments from partnerships like United Therapeutics for orphan lung disease products including Tyvaso DPI and development-stage programs. Competition comes from major pharmaceutical companies offering alternative diabetes and heart failure therapies, with MannKind differentiating on factors including ease of administration, therapeutic efficacy, and safety profiles.